Page last updated: 2024-10-15

octaarginine

Description

octaarginine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156963561
MeSH IDM0416632

Synonyms (1)

Synonym
octaarginine

Research Excerpts

Overview

Octaarginine (R8) is a representative cell-penetrating peptide.

ExcerptReference
"Octaarginine (R8) is a representative cell-penetrating peptide. "( Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking.
Chiba, J; Futaki, S; Hatanaka, Y; Imanishi, M; Kawaguchi, Y; Nakase, I; Tanaka, G, 2013
)

Toxicity

ExcerptReference
" In vitro toxicity studies demonstrated that the hyaluronic acid derivative was much less toxic than the corresponding PNVA- co-AA derivatives, and that both the polymers and their metabolites did not exhibit genotoxicity."( Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination.
Baba, M; Sakuma, S; Shigeno, K; Tanishita, S; Tobita, E; Tomono, T; Ukawa, M; Uto, T; Yagi, H; Yoshida, Y, 2019
)

Compound-Compound Interactions

ExcerptReference
" Here, we investigated whether intracellular delivery of the drug fosmidomycin can be improved by combination with the CPP octaarginine."( Improved efficacy of fosmidomycin against Plasmodium and Mycobacterium species by combination with the cell-penetrating peptide octaarginine.
Amulic, B; Gengenbacher, M; Kamena, F; Kolesinska, B; Matuschewski, K; Purkayastha, N; Seebach, D; Sparr, C, 2013
)

Bioavailability

ExcerptReference
" The mean bioavailability was 20% relative to subcutaneous administration, even though it fell short of 1% when exendin-4 alone was administered nasally."( Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.
Fujii, K; Higashitarumi, S; Hiwatari, KI; Ishizaki, S; Kobayashi, H; Kumagai, H; Miyata, K; Mohri, K; Ochiai, K; Sakuma, S; Shigeno, K; Tanishita, S; Tobita, E; Tsubaki, K; Ukawa, M; Yamada, M, 2018
)
"Our previous mouse studies demonstrated that mean bioavailability of exendin-4, which is an injectable glucagon-like peptide-1 (GLP-1) analogue whose molecular weight (Mw) and isoelectric point (pI) are ca."( Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
Igi, R; Ishizaki, S; Kobayashi, H; Kumagai, H; Miwa, T; Miyata, K; Nonomura, M; Sakuma, S; Tobita, E; Tomono, T; Ukawa, M; Yagi, H, 2020
)

Dosage Studied

ExcerptReference
" This pharmacokinetic disadvantage has largely restricted the development of noninvasive dosage forms of biologics that deliver into systemic circulation."( Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.
Fujii, K; Higashitarumi, S; Hiwatari, KI; Ishizaki, S; Kobayashi, H; Kumagai, H; Miyata, K; Mohri, K; Ochiai, K; Sakuma, S; Shigeno, K; Tanishita, S; Tobita, E; Tsubaki, K; Ukawa, M; Yamada, M, 2018
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (124)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's27 (21.77)29.6817
2010's84 (67.74)24.3611
2020's13 (10.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other120 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]